SHAREHOLDER ACTION ALERT: Law Firm Schall Encourages Revance Therapeutics, Inc. Investors With Losses Of $ 100,000 To Contact Firm
LOS ANGELES–(COMMERCIAL THREAD) –Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. (âRevanceâ or âthe Companyâ) (NASDAQ: RVNC) for violations of Â§Â§10 (b) and 20 (a) of the Securities Exchange Act of 1934 and rule 10b-5 promulgated thereunder by the United States Securities and Exchange Commission.
Investors who purchased the Company’s securities between November 25, 2019 and October 11, 2021 inclusive (the âRecourse Periodâ), are invited to contact the company before February 8, 2022.
If you are a shareholder who has suffered a loss, Click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected]
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by legal counsel. If you choose not to take any action, you can remain an absent member of the group.
According to the complaint, the company made false and misleading statements to the market. Revance’s DaxibotulinumtoxinA for Injection (âDAXIâ) manufacturing plant suffered from quality control issues. These manufacturing issues have reduced the chances that the FDA will approve the Company’s Biologics License Application (âBLAâ) for DAXI, particularly within the timeline announced by the Company to investors. Based on these facts, the Company’s public statements were false and misleading throughout the Class Period. When the market learned the truth about Revance, investors suffered damage.
Join the case to recoup your losses.
Schall law firm represents investors around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered an attorney’s advertisement in certain jurisdictions under applicable law and rules of professional conduct.